Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa.
作者信息
Collie Shirley, Nayager Jiren, Bamford Lesley, Bekker Linda-Gail, Zylstra Matt, Gray Glenda
机构信息
Discovery Health, Sandton, South Africa.
National Department of Health, Pretoria, South Africa.
出版信息
N Engl J Med. 2022 Oct 6;387(14):1332-1333. doi: 10.1056/NEJMc2210093. Epub 2022 Sep 14.
Abstract
摘要
相似文献
1
Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa.BNT162b2疫苗在南非针对奥密克戎亚谱系的有效性和持久性
N Engl J Med. 2022 Oct 6;387(14):1332-1333. doi: 10.1056/NEJMc2210093. Epub 2022 Sep 14.
2
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.第三次BNT162b2疫苗接种对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎感染的中和作用
N Engl J Med. 2022 Feb 3;386(5):492-494. doi: 10.1056/NEJMc2119358. Epub 2021 Dec 29.
3
Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa.Ad26.COV2.S和BNT162b2疫苗在南非针对奥密克戎变种的有效性
N Engl J Med. 2022 Jun 9;386(23):2243-2245. doi: 10.1056/NEJMc2202061. Epub 2022 May 4.
4
Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years - PROTECT Cohort, July 2021-February 2022.2 剂 BNT162b2（辉瑞-生物科技）mRNA 疫苗预防 5-11 岁儿童和 12-15 岁青少年感染 SARS-CoV-2 的效果 - PROTECT 队列，2021 年 7 月至 2022 年 2 月。
MMWR Morb Mortal Wkly Rep. 2022 Mar 18;71(11):422-428. doi: 10.15585/mmwr.mm7111e1.
5
Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.韩国医护人员接种第二剂 BNT162b2 mRNA 疫苗 6 个月后仍保持对 SARS-CoV-2 的抗体应答。
Front Immunol. 2022 Jan 31;13:827306. doi: 10.3389/fimmu.2022.827306. eCollection 2022.
6
Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations.Ad26.COV2.S 疫苗与 BNT162b2 疫苗对 COVID-19 住院治疗的有效性。
JAMA Netw Open. 2022 Mar 1;5(3):e220868. doi: 10.1001/jamanetworkopen.2022.0868.
7
The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.奥密克戎变异株疫苗有效性的系统评价和荟萃分析。
Front Public Health. 2022 Jul 13;10:940956. doi: 10.3389/fpubh.2022.940956. eCollection 2022.
8
Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.以色列卫生保健工作者中，第三剂 BNT162b2 疫苗接种与 SARS-CoV-2 感染发生率的关联。
JAMA. 2022 Jan 25;327(4):341-349. doi: 10.1001/jama.2021.23641.
9
BNT162b2 Vaccine Effectiveness Against the SARS-CoV-2 Omicron Variant in Children Aged 5 to 11 Years.BNT162b2疫苗对5至11岁儿童中SARS-CoV-2奥密克戎变异株的有效性
JAMA Pediatr. 2023 Mar 1;177(3):319-320. doi: 10.1001/jamapediatrics.2022.5221.
10
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa.BNT162b2疫苗在南非针对奥密克戎变异株的有效性
N Engl J Med. 2022 Feb 3;386(5):494-496. doi: 10.1056/NEJMc2119270. Epub 2021 Dec 29.
引用本文的文献
1
Peptide immunoarrays for rationale development of vaccines with enhanced cross-reactivity.用于合理开发具有增强交叉反应性疫苗的肽免疫阵列。
PLoS One. 2025 Sep 4;20(9):e0330741. doi: 10.1371/journal.pone.0330741. eCollection 2025.
2
Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial.单价奥密克戎KP.2适应性BNT162b2新冠疫苗在成人中的安全性和免疫原性：一项2/3期试验的单臂子研究
Infect Dis Ther. 2025 Jul 1. doi: 10.1007/s40121-025-01185-4.
3
Comparative duration of neutralizing responses and protections of COVID-19 vaccination and correlates of protection.新冠疫苗中和抗体反应和保护作用的比较持续时间以及保护相关因素。
Nat Commun. 2025 May 22;16(1):4748. doi: 10.1038/s41467-025-60024-9.
4
Intensity of public health and social measures are associated with effectiveness of SARS-CoV-2 vaccine in test-negative study.在阴性对照研究中，公共卫生和社会措施的强度与SARS-CoV-2疫苗的有效性相关。
medRxiv. 2025 May 8:2025.05.08.25327221. doi: 10.1101/2025.05.08.25327221.
5
The impact of pre-existing immunity on the emergence of within-host immune-escape mutations in Omicron lineages.既往免疫对奥密克戎谱系宿主内免疫逃逸突变出现的影响。
J Gen Virol. 2025 May;106(5). doi: 10.1099/jgv.0.002108.
6
Beyond the Pandemic Era: Recent Advances and Efficacy of SARS-CoV-2 Vaccines Against Emerging Variants of Concern.后疫情时代：SARS-CoV-2疫苗针对新出现的关注变异株的最新进展与效果
Vaccines (Basel). 2025 Apr 17;13(4):424. doi: 10.3390/vaccines13040424.
7
SARS-CoV-2 conjugate vaccine elicits robust immune responses that can protect against evolving variants.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）结合疫苗可引发强大的免疫反应，能够抵御不断演变的病毒变体。
Vaccine. 2025 Apr 30;54:126988. doi: 10.1016/j.vaccine.2025.126988. Epub 2025 Mar 6.
8
Effectiveness of mass vaccination for prevention of hospitalization, severe disease and death due to SARS-CoV-2 omicron Ba.2 variant; A case-population study.大规模接种疫苗预防SARS-CoV-2奥密克戎BA.2变异株所致住院、重症和死亡的有效性：一项病例人群研究。
Heliyon. 2025 Feb 12;11(4):e42670. doi: 10.1016/j.heliyon.2025.e42670. eCollection 2025 Feb 28.
9
Impact of COVID-19 vaccination on hospitalization, hospital utilization and expenditure for COVID-19: A retrospective cohort analysis of a South African private health insured population.新冠疫苗接种对新冠病毒感染住院情况、医院利用及支出的影响：一项针对南非有私人医疗保险人群的回顾性队列分析
PLoS One. 2025 Jan 24;20(1):e0317686. doi: 10.1371/journal.pone.0317686. eCollection 2025.
10
Genomic surveillance and vaccine response to the dominant SARS-CoV-2 XBB lineage in Rio Grande do Sul.基因组监测和针对南里奥格兰德州主要 SARS-CoV-2 XBB 谱系的疫苗反应。
Sci Rep. 2024 Jul 22;14(1):16831. doi: 10.1038/s41598-024-67828-7.
本文引用的文献
1
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa.BNT162b2疫苗在南非针对奥密克戎变异株的有效性
N Engl J Med. 2022 Feb 3;386(5):494-496. doi: 10.1056/NEJMc2119270. Epub 2021 Dec 29.
Zotero 插件